Management of hyperlipidemia with statins in the older patient by Aronow, Wilbert S
Clinical Interventions in Aging 2006:1(4) 433–438
© 2007 Dove Medical Press Limited. All rights reserved
433
REVIEW
Abstract: Numerous randomized, double-blind, placebo-controlled studies and observational 
studies have demonstrated that statins decrease mortality and major cardiovascular events in 
older high-risk persons with hypercholesterolemia. The Heart Protection Study found that 
statins decreased mortality and major cardiovascular events in high-risk persons regardless of 
the initial level of serum lipids, age, or gender. The updated National Cholesterol Education 
Program (NCEP) III guidelines state that in very high-risk patients, a serum low-density 
lipoprotein (LDL) cholesterol level of <70 mg/dl is a reasonable clinical strategy, regardless of 
age. When a high-risk person has hypertriglyceridemia or low serum high-density lipoprotein 
cholesterol, consideration can be given to combining a ﬁ  brate or nicotinic acid with an LDL 
cholesterol-lowering drug. For moderately high-risk persons (2 or more risk factors and a 
10-year risk for coronary heart disease of 10% to 20%), the serum LDL cholesterol should be 
decreased to <100 mg/dl. When LDL cholesterol-lowering drug therapy is used to treat high-
risk persons or moderately high-risk persons, the serum LDL cholesterol should be decreased 
at least 30% to 40%.
Keywords: lipids, statins, lipid-lowering drugs, coronary heart disease, atherosclerotic vascular 
disease
Introduction
Numerous randomized, double-blind, placebo-controlled studies and observational 
studies have demonstrated that 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) 
reductase inhibitors (statins) reduce mortality and major cardiovascular events in 
high-risk older persons with hypercholesterolemia. The Heart Protection Study (HPS) 
showed that statins reduced mortality and major cardiovascular events in high-risk 
persons regardless of the initial level of serum lipids, age, or gender (HPS 2002). This 
paper will discuss the studies showing that statins decrease cardiovascular morbidity 
and mortality in high-risk older persons and discuss the updated National Cholesterol 
Education Program III (NCEP-III) guidelines for treatment of high-risk persons with 
lipid-lowering therapy.
Randomized, double-blind, placebo-controlled 
studies
In 4444 men and women with coronary heart disease (CHD) and hypercholesterolemia 
in the Scandinavian Simvastatin Survival Study, compared with placebo, simvastatin 
20 mg to 40 mg daily decreased serum total cholesterol by 25%, serum low-density 
lipoprotein (LDL) cholesterol by 35%, and serum triglycerides by 10%, and increased 
serum high-density lipoprotein (HDL) cholesterol by 8% (SSS 1994; Miettinen et 
al 1997; Pedersen et al 1998; Pedersen et al 2000).  At 5.4-year median follow-up, 
compared with placebo, simvastatin signiﬁ  cantly reduced all-cause mortality by 30%, 
CHD death by 42%, nonfatal myocardial infarction (MI) by 33%, major coronary 
events by 34%, cerebrovascular events by 30%, any atherosclerosis-related endpoint by 
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34%, coronary revascularization by 37%, new or worsening 
angina pectoris by 26%, intermittent claudication by 38%, 
and arterial bruits by 30% (SSS 1994; Miettinen et al 1997; 
Pedersen et al 1998). Decreases in endpoint events were 
similar in older and younger men and women. The absolute 
risk reduction for both all-cause mortality and CHD mortality 
was approximately twice as great in persons 65 years of age 
and older as in those younger than 65 years of age (Miettinen 
et al 1997). At 7.4-year median follow-up, simvastatin 
signiﬁ  cantly reduced all-cause mortality by 30% and CHD 
mortality by 38% (Pedersen et al 2000). 
In the Cholesterol and Recurrent Events study involving 
pravastatin therapy for a period of 5 years in 4159 post-MI 
patients and serum total cholesterol levels <240 mg/dl and 
serum LDL cholesterol levels of 115 mg/dl to 174 mg/dl, 
compared with placebo, pravastatin 40 mg daily lowered 
serum total cholesterol by 20%, serum LDL cholesterol by 
32%, and serum triglycerides by 14%, and raised serum HDL 
cholesterol by 5% (Sacks et al 1996; Lewis et al 1998). At 
5-year median follow-up, compared with placebo, pravastatin 
signiﬁ  cantly reduced CHD death or nonfatal MI by 24%, 
stroke by 31%, coronary artery bypass graft surgery by 
26%, and coronary angioplasty by 23% (Sacks et al 1996). 
For every 1000 patients aged 65 to 75 years treated for 
5 years with pravastatin, 225 cardiovascular hospitalizations 
would be prevented compared with prevention of 121 
cardiovascular hospitalizations in 1000 younger patients 
(Lewis et al 1998).
The Long-Term Intervention with Pravastatin in 
Ischaemic Disease (LIPID) study randomized 9014 patients 
with a history of MI or unstable angina pectoris who had initial 
serum total cholesterol levels of 155 mg/dl to 271 mg/dl
to pravastatin 40 mg daily or placebo (LIPID 1998, 2002). 
Compared with placebo, pravastatin lowered serum total 
cholesterol by 18%, serum LDL cholesterol by 25%, serum 
triglycerides by 11%, and raised serum HDL cholesterol 
by 5%. At 6.1-year follow-up, compared with placebo, 
pravastatin signiﬁ  cantly lowered all-cause mortality by 
22%, death from CHD or nonfatal MI by 24%, nonfatal MI 
by 29%, stroke by 19%, and coronary revascularization by 
20% (LIPID 1998). Treatment of 1000 patients for 6 years 
with pravastatin prevented 30 deaths, 28 nonfatal MIs, 
9 nonfatal strokes, 23 episodes of coronary artery bypass graft 
surgery, 20 episodes of coronary angioplasty, and 82 hospital 
admissions for unstable angina pectoris (LIPID 1998). The 
absolute beneﬁ  ts of therapy with pravastatin were greater 
in groups at higher absolute risk for a major coronary event 
such as persons aged 65 to 75 years, those with low serum 
HDL cholesterol levels, and those with a history of diabetes 
mellitus or smoking (LIPID 1998). At 8-year follow-up, 
pravastatin signiﬁ  cantly lowered all-cause mortality by 18%, 
CHD death by 25%, and CHD death or nonfatal MI by 17% 
(LIPID 2002).
The HPS randomized 20 536 men and women with 
prior MI (8510 persons), other CHD (4876 persons), and no 
CHD (7150 persons) and a serum total cholesterol level of 
135 mg/dl or higher to simvastatin 40 mg daily or to placebo 
(HPS 2002). Of the 7150 persons without CHD, 25% had 
cerebrovascular disease, 38% had peripheral arterial disease 
(PAD), 56% had diabetes mellitus, and 3% had only treated 
hypertension without atherosclerotic vascular disease or 
diabetes mellitus. Compared with placebo, simvastatin 
decreased serum LDL cholesterol by 39% (HPS 2002). 
At 5-year follow-up, compared with placebo, simvastatin 
significantly lowered all-cause mortality by 13%, any 
cardiovascular death by 17%, major coronary events by 27%, 
any stroke by 25%, coronary or noncoronary revascularization 
by 24%, and any major cardiovascular event by 24% (HPS 
2002). These significant decreases in mortality and in 
cardiovascular events occurred regardless of initial levels 
of serum lipids, age, or gender. First major cardiovascular 
event was signiﬁ  cantly lowered by simvastatin by 24% in 
patients younger than 65 years, by 23% in patients aged 65 
to 69 years, and by 18% in patients aged 70 to 80 years at 
study entry. Five years of simvastatin treatment prevented MI, 
stroke, and revascularization in 70 to 100 persons per 1000 
treated patients.
In the HPS, 3500 patients had initial serum LDL 
cholesterol levels <100 mg/dl. Reduction of serum LDL 
cholesterol from 97 mg/dl to 65 mg/dl by simvastatin in these 
patients who would not be treated according to NCEP-III 
guidelines (NCEP 2001) caused a similar reduction in risk as 
did treating patients with higher serum LDL cholesterol levels. 
The HPS Investigators recommended treating persons at high 
risk for cardiovascular events with statins, regardless of the 
initial levels of serum lipids, age, or gender (HPS 2002).
The Prospective Study of Pravastatin in the Elderly at 
Risk study randomized 5804 men and women aged 70 to 
82 years with a history of or risk factors for cardiovascular 
disease and a serum total cholesterol level of 154 mg/dl or 
higher to pravastatin 40 mg daily or placebo (Shepherd et al 
2002). Compared with placebo, pravastatin lowered serum 
total cholesterol by 32% and serum triglycerides by 12%, and 
raised serum HDL cholesterol by 5%. At 3.2-year follow-up, Clinical Interventions in Aging 2006:1(4) 435
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the primary endpoint of CHD death, nonfatal MI, or stroke 
was signiﬁ  cantly reduced to 15% by pravastatin compared 
with placebo. CHD death or nonfatal MI was signiﬁ  cantly 
lowered to 19% by pravastatin. Stroke risk was unaffected 
but pravastatin signiﬁ  cantly lowered the risk for transient 
ischemic attack by 25%. 
In the Myocardial Ischemia Reduction with Aggressive 
Cholesterol Lowering study, 3086 patients with an acute 
coronary syndrome and a mean serum LDL cholesterol level 
of 124 mg/dl were randomized to atorvastatin 80 mg daily or 
to placebo 24 to 96 hours after hospitalization for 16 weeks 
(Schwartz et al 2001). At the end of the study, the serum LDL 
cholesterol increased 12% to 135 mg/dl in the placebo group 
and decreased 40% to 72 mg/dl in the atorvastatin group. At 
16-week follow-up, compared with placebo, atorvastatin 
signiﬁ  cantly lowered mortality, nonfatal MI, cardiac arrest 
with resuscitation, or recurrent symptomatic myocardial 
ischemia with objective evidence and requiring emergency 
rehospitalization by 16% and stroke by 50%.
 Sixty-nine older patients, mean age 75 years, with 
intermittent claudication due to peripheral arterial disease 
(PAD) and hypercholesterolemia were randomized to 
simvastatin 40 mg daily or to placebo (Aronow et al 2003). 
Compared with placebo, simvastatin signiﬁ  cantly increased 
treadmill exercise time until the onset of intermittent 
claudication by 24% at 6 months after treatment and by 42% 
at 1 year after treatment. 
In a study of 354 patients, mean age 68 years, with inter-
mittent claudication due to PAD and hypercholesterolemia 
randomized to atorvastatin 80 mg daily or placebo, at 1-year 
follow-up, compared with placebo, atorvastatin 80 mg daily 
signiﬁ  cantly improved pain-free treadmill walking distance 
by 40% and community-based physical activity (Mohler 
et al 2003). In another study of 86 patients, mean age 
67 years, with intermittent claudication due to PAD and 
hypercholesterolemia, at 6-month follow-up, compared with 
placebo, simvastatin 40 mg daily signiﬁ  cantly improved 
pain-free walking distance and total walking distance on a 
treadmill, signiﬁ  cantly improved the mean ankle-brachial 
index at rest and after exercise, and signiﬁ  cantly improved 
symptoms of claudication (Mondillo et al 2003).
In the Lipid Lowering Arm of the Anglo-Scandinavian 
Cardiac Outcomes trial, 10 305 patients with hypertension 
and at least 3 other cardiovascular risk factors with no 
history of CHD and a mean serum LDL cholesterol of 
133 mg/dl were randomized to atorvastatin 10 mg daily or to 
placebo (Sever et al 2003). At 3.3-year follow-up, the serum 
LDL cholesterol was 90 mg/dl in persons treated with 
atorvastatin. At 3.3-year follow-up, compared with placebo, 
atorvastatin signiﬁ  cantly lowered the incidence of fatal CHD 
and nonfatal MI by 36%, fatal and nonfatal stroke by 27%, 
coronary events by 29%, and cardiovascular events and 
procedures by 21%. 
In the Collaborative Atorvastatin Diabetes Study, 2838 
patients with diabetes mellitus, no cardiovascular disease, 
and a serum LDL cholesterol <160 mg/dl were randomized 
to atorvastatin 10 mg daily or placebo (Calhoun et al 2004). 
At 3.9-year median follow-up, compared with placebo, 
atorvastatin signiﬁ  cantly decreased time to ﬁ  rst occurrence 
of acute CHD events, coronary revascularization, or 
stroke by 37%, acute coronary events by 36%, and stroke 
by 48%.
In the Reversal of Atherosclerosis with Aggressive 
Lipid Lowering study, intravascular ultrasound was used to 
measure progression of atherosclerosis in 502 patients with 
CHD randomized to pravastatin 40 mg daily or atorvastatin 
80 mg daily (Nissen et al 2004). The serum LDL cholesterol 
was lowered to 110 mg/dl in the pravastatin group and to 
79 mg/dl in the atorvastatin group. At 18-month follow-
up, compared with baseline values, patients treated with 
atorvastatin had no change in atheroma burden, whereas 
patients treated with pravastatin showed progression of 
coronary atherosclerosis.
In 4162 patients, mean age 58 ± 11 years, hospitalized 
for an acute coronary syndrome (29% with unstable angina 
pectoris and 71% with an acute MI), the median serum 
LDL cholesterol was 95 mg/dl in patients randomized 
to pravastatin 40 mg daily versus 62 mg/dl in patients 
randomized to atorvastatin 80 mg daily (Cannon et al 2004). 
At 2-year follow-up, the primary end point of death from any 
cause, MI, documented unstable angina pectoris requiring 
rehospitalization, coronary revascularization (performed at 
least 30 days after randomization), and stroke was 26.3% in 
the pravastatin group versus 22.4% in the atorvastatin group, 
a signiﬁ  cant 16% reduction in favor of atorvastatin. Data 
from patients, mean age 61 years, also support early intensive 
therapy with simvastatin coupled with revascularization 
when appropriate after an acute coronary syndrome (de Lemos 
et al 2004). 
In 10 001 patients, mean age 61 years, with stable CHD 
and a serum LDL cholesterol level <130 mg/dl, the effect of 
atorvastatin 10 mg daily versus 80 mg daily was investigated 
in a randomized, double-blind trial (LaRosa et al 2005). The 
mean serum LDL cholesterol levels were 77 mg/dl in patients Clinical Interventions in Aging 2006:1(4) 436
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treated with atorvastatin 80 mg daily versus 101 mg/dl in 
patients treated with atorvastatin 10 mg daily. At 4.9-year 
median follow-up, the primary endpoint of a ﬁ  rst major 
cardiovascular event was signiﬁ  cantly reduced 22% by 
atorvastatin 80 mg daily.
A prospective meta-analysis of data from 90 056 
participants in 14 randomized secondary prevention and 
primary prevention trials of statins was performed (CTT 
2005). This meta-analysis showed that statin therapy can safely 
lower the 5-year incidence of major coronary events, coronary 
revascularization, and stroke by about one-ﬁ  fth per 38.7 mg/dl 
reduction in serum LDL cholesterol, irrespective of the initial 
lipid proﬁ  le or other presenting characteristics. The absolute 
beneﬁ  t related chieﬂ  y to a person’s absolute risk of such 
events and to the absolute reduction in serum LDL cholesterol 
achieved. These ﬁ  ndings reinforce the need to give prolonged 
statin therapy with substantial serum LDL cholesterol reduction 
in all patients at high risk of any type of major vascular event.
This meta-analysis also showed that statins did not cause 
an increase in any site-speciﬁ  c cancer. The 5-year excess risk 
with statin use of rhabdomyolysis was 0.01%.
Observational studies
In an observational prospective study of 1410 patients, mean 
age 81 years, with prior MI and a serum LDL cholesterol of 
125 mg/dL or higher, 48% of patients were treated with statins 
(Aronow and Ahn 2002a, 2002b; Aronow et al 2002a). At
3-year follow-up, compared with no treatment with statins, 
use of statins signiﬁ  cantly decreased CHD death or nonfatal 
MI by 50% (Aronow and Ahn 2002a), stroke by 60% 
(Aronow et al 2002a) and heart failure by 48% (Aronow 
et al 2002b). Statins signiﬁ  cantly decreased new coronary 
events in patients older than 90 years (12% of persons at 
entry) (Aronow and Ahn 2002a). Statins signiﬁ  cantly reduced 
new stroke in patients aged 90 years and younger but not in 
patients older than 90 years (Aronow et al 2002a).
Lowering serum LDL cholesterol to <90 mg/dl was 
associated with a 20% incidence of new coronary events, 
whereas decreasing serum LDL cholesterol to 90–99 mg/dl 
was associated with a 48% incidence of new coronary events 
(Aronow and Ahn 2002a). The lower the serum LDL 
cholesterol in older persons treated with statins, the greater 
was the decrease in new coronary events (Aronow and Ahn 
2002a). Decreasing serum LDL cholesterol to <90 mg/dl 
was associated with a 7% incidence of new stroke, whereas 
decreasing serum LDL cholesterol to 90–99 mg/dl was 
associated with a 16% incidence of new stroke (Aronow et al 
2002a).The lower the serum LDL cholesterol in older patients 
treated with statins, the greater the decrease in new stroke 
(Aronow et al 2002a).
In an observational prospective study of 1410 patients, 
mean age 81 years, with prior MI and a serum LDL cholesterol 
level of 125 mg/dl or higher, patients treated with aspirin 
had a 52% signiﬁ  cant decrease in new coronary events at
3-year follow-up (Aronow and Ahn 2002c). Patients treated 
with statins (49%) had a 54% signiﬁ  cant decrease in coronary 
events independent of the use of aspirin.
In an observational prospective study of 529 patients, 
mean age 79 years, with prior MI, diabetes mellitus, and 
a serum LDL cholesterol of 125 mg/dl or higher, 53% of 
patients were treated with statins (Aronow et al 2002b). 
At 29-month follow-up, compared with no treatment with 
statins, use of statins signiﬁ  cantly lowered CHD death or 
nonfatal MI by 37% and stroke by 47%. 
In an observational prospective study of 660 patients, 
mean age 80 years, with symptomatic PAD and a serum LDL 
cholesterol of 125 mg/dl or higher, 48% of patients were 
treated with statins (Aronow and Ahn 2002d). At 39-month 
follow-up, compared with no treatment with statins, use of 
statins signiﬁ  cantly reduced CHD death or nonfatal MI by 
52% in patients with prior MI and by 59% in patients with 
no prior MI.
In a study of 551 patients with congestive heart failure 
and an abnormal left ventricular ejection fraction due to 
ischemic or nonischemic heart disease, 45% of the patients 
were treated with statins (Horwich et al 2004). At 1-year 
follow-up, the use of statins was associated with a signiﬁ  cant 
59% decrease in mortality. 
In a study of 54 960 Medicare patients, mean age 79 years, 
with congestive heart failure and no contraindications to 
statins, use of statins (17% of group) signiﬁ  cantly reduced 
1-year mortality by 20% and 3-year mortality by 18% 
(Foody et al 2006). Statins also significantly reduced 
progression of valvular aortic stenosis in 180 patients, mean 
age 82 years (Aronow et al 2001), in 174 patients, mean age 
68 years (Novaro et al 2001), and in 156 patients, mean age 
77 years (Bellamy et al 2002).
In the ASTEROID trial, 349 patients, mean age 59 years, 
with coronary atherosclerosis treated with rosuvastatin 
which lowered the baseline serum LDL cholesterol from 
130 mg/dl to 61 mg/dl and increased the baseline serum 
HDL cholesterol from 43 mg/dl to 49 mg/dl had intravascular 
ultrasound evaluations at baseline and after 24 months of 
therapy (Nissen et al 2006). At 2-year follow-up, patients Clinical Interventions in Aging 2006:1(4) 437
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treated with rosuvastatin had significant regression of 
atherosclerosis for all 3 prespeciﬁ  ed measures of disease 
burden. 
Treatment guidelines
The NCEP-III guidelines recommended that the serum LDL 
cholesterol be decreased to <100 mg/dl in patients with 
CHD, other clinical forms of atherosclerotic vascular disease, 
diabetes mellitus, and with 2+ risk factors that conferred a 
10-year risk for CHD greater than 20%, regardless of age 
(NCEP 2001). Patients with 2+ risk factors that conferred 
a 10-year risk for CHD of 10% to 20% were recommended 
to have their serum LDL cholesterol reduced to less than 
130 mg/dl. These guidelines needed to be modiﬁ  ed because 
of data published since these guidelines were recommended 
(Aronow 2004). 
The updated NCEP III guidelines (Table 1) state that 
in very high-risk patients, a serum LDL cholesterol level 
of <70 mg/dl is a reasonable clinical strategy (Grundy et al 
2004). When a high-risk person has hypertriglyceridemia 
or low serum HDL cholesterol, consideration can be 
given to combining a ﬁ  brate or nicotinic acid with an LDL 
cholesterol-lowering drug. For moderately high-risk persons 
(2 or more risk factors and a 10-year risk for CHD of 10% 
to 20%) the serum LDL cholesterol should be reduced to 
less than 100 mg/dl. When LDL cholesterol-lowering drug 
therapy is used to treat high-risk persons or moderately high-
risk persons, the serum LDL cholesterol should be reduced 
at least 30% to 40%. 
Combination lipid-lowering 
drug therapy
In order, rosuvastatin, atorvastatin, and simvastatin are the 
3 most potent statins in lowering serum LDL cholesterol 
(Jones et al 2003). If the serum LDL cholesterol cannot 
be lowered to goal level by a high dose of a potent statin, 
ezetimide, a bile acid sequestrant, or nicotinic acid should 
be added to the therapeutic regimen (Grundy et al 2004). 
Ezetimide is a cholesterol absorption inhibitor that inhibits 
dietary and biliary cholesterol absorption at the brush border 
of the small intestine and would be the author’s choice 
to combine with a statin. Ezetimide is also marketed in 
combination with different doses of simvastatin as Vytorin. 
Unlike nicotinic acid, ezetimide and bile acid sequestrants 
do not increase the incidence of myopathy when combined 
with a statin.
If a high-risk person has hypertriglyceridemia or a low 
serum HDL cholesterol, consideration can be given to 
combining a ﬁ  brate or nicotinic acid with an LDL cholesterol-
lowering drug. When serum triglycerides are ≥200 mg/dl, 
non-HDL cholesterol is a secondary target of therapy, 
with a goal 30 mg/dl higher than the recommended serum 
LDL cholesterol goal (Grundy et al 2004). If a fibrate 
is administered together with a statin, fenoﬁ  brate rather 
than gemﬁ  brozil should be used since fenoﬁ  brate does not 
interfere with catabolism of statins and does not substantially 
increase the risk for clinical myopathy as does gemﬁ  brozil 
(Prucksaritanont et al 2002).
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